Dimerix DMX-652 Granted Mexican Composition of Matter Patent

Key points

• Composition of matter patent granted in Mexico for DMX-652
• Strengthens Dimerix's global intellectual property portfolio for DMX-652
• Enhances commercial attractiveness and value of DMX-652
• Preparations underway for DMX-652 Phase 2 clinical trial in AKI
• Mexico's pharmaceutical market is over US$15 billion

Full summary

Dimerix Limited, a clinical-stage biopharmaceutical company, announced that the Mexican Institute of Industrial Property has granted a composition of matter patent for its drug candidate DMX-652. This patent, which provides protection until 2041, strengthens Dimerix's intellectual property portfolio and enhances the commercial potential of DMX-652, a USP30 inhibitor being developed for acute kidney injury (AKI) and other indications. The grant complements the recently granted U.S. composition of matter patent. DMX-652 is a first-in-class drug designed to prevent kidney injury and promote mitophagy. Dimerix is preparing for a Phase 2 clinical trial of DMX-652 in AKI associated with cardiac surgery.